Thomas F Gajewski Selected Research

Thomas F Gajewski Research Topics

Disease

132	Neoplasms (Cancer) 01/2022 - 04/2002
64	Melanoma (Melanoma, Malignant) 01/2022 - 06/2003
13	Bites and Stings (Sting) 01/2020 - 11/2014
9	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2003
7	COVID-19 01/2022 - 01/2020
7	Disease Progression 01/2018 - 02/2003
6	Renal Cell Carcinoma (Grawitz Tumor) 11/2016 - 04/2002
3	Fever (Fevers) 01/2021 - 09/2017
3	Brain Neoplasms (Brain Tumor) 01/2019 - 12/2012
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2018 - 01/2016
3	Fatigue 09/2017 - 08/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2016 - 02/2003
3	Experimental Melanoma 03/2012 - 05/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2013
2	Exanthema (Rash) 01/2019 - 08/2014
2	Anemia 01/2018 - 02/2015
2	Leukemia 01/2018 - 01/2006
2	Ascites 01/2018 - 10/2006
2	Uveal melanoma 03/2017 - 06/2014
2	Hypersensitivity (Allergy) 01/2017 - 02/2010
2	Nausea 02/2015 - 08/2014
2	Myalgia 08/2014 - 02/2003
2	Inflammation (Inflammations) 04/2013 - 01/2012
1	Multiple Myeloma 01/2022
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2022
1	Wilms Tumor (Wilm's Tumor) 01/2022
1	Neuroblastoma 01/2022
1	Infections 01/2022
1	Carcinogenesis 01/2022
1	Rhabdoid Tumor (Rhabdoid Tumors) 01/2022
1	Osteosarcoma (Osteogenic Sarcoma) 01/2022

Drug/Important Bio-Agent (IBA)

19	AntigensIBA 01/2022 - 12/2002
19	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 12/2002
13	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
11	VaccinesIBA 01/2022 - 03/2004
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2004
11	CytokinesIBA 11/2016 - 05/2002
10	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2010
10	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 11/2014
9	IpilimumabIBA 01/2021 - 10/2010
8	Peptides (Polypeptides)IBA 11/2019 - 06/2003
7	pembrolizumabIBA 01/2021 - 01/2016
7	ChemokinesIBA 01/2021 - 10/2006
7	Biological ProductsIBA 07/2020 - 05/2002
7	Interferon Type IIBA 01/2019 - 09/2011
7	Interleukin-2 (IL2)IBA 01/2014 - 05/2002
6	AntibodiesIBA 01/2022 - 06/2013
6	Monoclonal AntibodiesIBA 01/2021 - 07/2006
6	CateninsIBA 11/2019 - 01/2015
6	LigandsIBA 01/2019 - 01/2004
6	B7-H1 AntigenIBA 09/2017 - 04/2005
5	InterferonsIBA 01/2018 - 11/2014
4	Pharmaceutical PreparationsIBA 01/2021 - 12/2011
4	NivolumabIBA 01/2020 - 01/2016
4	VemurafenibIBA 01/2020 - 07/2012
4	epacadostatIBA 01/2019 - 01/2017
4	cyclic guanosine monophosphate-adenosine monophosphateIBA 04/2016 - 11/2014
3	SteroidsIBA 01/2022 - 06/2004
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2008
3	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 09/2013
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2016
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2020
2	Nucleic AcidsIBA 01/2021 - 12/2020
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021 - 07/2020
2	C-Reactive ProteinIBA 01/2021 - 07/2020
2	tocilizumab (atlizumab)FDA Link 01/2021 - 07/2020
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 07/2020
2	cobimetinibIBA 01/2020 - 08/2014
2	Interleukin-12 (IL 12)IBA 11/2019 - 06/2003
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 11/2015
2	EnzymesIBA 11/2018 - 08/2014
2	Monatide (IMS 3015)IBA 01/2018 - 01/2013
2	Sirolimus (Rapamycin)FDA Link 01/2018 - 09/2012
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2017 - 08/2014
2	AZD 6244IBA 03/2017 - 06/2014
2	Immunomodulating AgentsIBA 11/2016 - 04/2012
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2016 - 02/2004
2	Interferon Regulatory Factor-3 (Interferon Regulatory Factor 3)IBA 04/2016 - 11/2014
2	Blocking AntibodiesIBA 01/2016 - 11/2015
2	Mitogen-Activated Protein KinasesIBA 11/2015 - 06/2014
2	Therapeutic UsesIBA 11/2015 - 05/2015
2	Tyrosine Kinase InhibitorsIBA 05/2015 - 06/2004
2	Temozolomide (Temodar)FDA LinkGeneric 06/2014 - 02/2004
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2013 - 02/2010
2	tipifarnib (R115777)IBA 12/2012 - 12/2004
2	EpitopesIBA 04/2012 - 01/2006
2	PerforinIBA 03/2012 - 10/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2008 - 06/2004
2	superagonist SIYRIBA 05/2008 - 02/2004
2	MART-1 AntigenIBA 10/2006 - 06/2003
1	Immunoglobulin G (IgG)IBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022

Therapy/Procedure

69	Immunotherapy 01/2022 - 04/2005
58	Therapeutics 01/2022 - 06/2003
11	Drug Therapy (Chemotherapy) 01/2022 - 04/2002
4	Radiotherapy 12/2020 - 11/2014
3	Biological Therapy 09/2011 - 09/2007
2	Precision Medicine 01/2021 - 11/2016
2	Premedication 06/2004 - 02/2003